§ Funding Round
Series C funding round for NiKang Therapeutics raising $200M in May 2021
Series C funding round for NiKang Therapeutics raising $200M in May 2021
| Investor | Firm Type | Partner |
|---|---|---|
| Organization | — | |
Ally Bridge Group | — | — |
| Organization | — | |
| Organization | — | |
CBC Group | — | — |
| Organization | — | |
| Organization | — | |
HBM Healthcare InvestmentsLEAD | — | — |
| Organization | — | |
Janus Henderson Investors | — | — |
| Organization | — | |
Logos Capital | — | — |
Matrix Partners China | — | — |
| Angel | zhenhai gao | |
ting jia (tj)LEAD | Angel | ting jia (tj) |
| Organization | — | |
| Organization | — | |
PFM Health Sciences | — | — |
| Organization | — | |
Samsara BioCapital | — | — |
Surveyor Capital | — | — |
| Organization | — |
This company has completed 2 funding rounds. Current round is highlighted.
Total Raised
$250M
Top Valuation
-
NiKang Therapeutics raised $200M in a Series C round.
The round was announced on 05/01/21.
The round was led by cormorant asset management, HBM Healthcare Investments, ting jia (tj).
